Disruption of Brca2-Rad51 Complex in Breast Cancer Cells: Therapeutic Implications

Abstract

BRCA2-Rad51 interaction is required for the Rad51-related DNA repair pathway. Thus, inhibition of their interaction is expected to sensitize tumor cells to certain DNA damaging agents. A panel of 14080 natural compounds from the Chinese National Center for Drug Screening has been partially screened using a yeast two-hybrid system utilizing specific Rad51/BRCA2 constructs. Growth of the Rad51/BRCA2 yeast strain in different media lead us to the selection of 20 candidate inhibitors for BRAC2-Rad51 interaction. We are actually testing if these compounds sensitize breast cancer cell lines to cisplatin. One of the compounds at the concentrations attainable increases the toxicity of cisplatin in a BRCA1 deficient breast cancer cell line.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2006
Accession Number
ADA462888

Entities

People

  • Raquel S. Aloyz

Organizations

  • Jewish General Hospital

Tags

DTIC Thesaurus Topics

  • Amino Acids
  • Biomedical Research
  • Breast Cancer
  • Cell Line
  • Cells
  • Culture Media
  • Gamma Rays
  • Genetic Structures
  • Genetics
  • Health Services
  • Hybrid Systems
  • Inhibition
  • Inhibitors
  • Ionizing Radiation
  • Neoplasms
  • Nitrogen Compounds
  • Toxicity

Readers

  • Cellular and Molecular Pathways of Apoptosis.
  • Molecular and genetic basis of cancer.
  • Systems Analysis and Design

Technology Areas

  • Biotechnology